TITLE:
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

CONDITION:
Cytomegalovirus Infections

INTERVENTION:
valganciclovir [Valcyte]

SUMMARY:

      This study will assess the safety and pharmacokinetics of Valcyte syrup in pediatric solid
      organ transplant recipients. The anticipated time on study treatment is 3-12 months and the
      target sample size is less than 100 individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 3 Months to 16 Years
Criteria:

        Inclusion Criteria:

          -  patients between 3 months and 16 years of age;

          -  first solid organ transplant (eg, kidney, liver, heart);

          -  able to tolerate oral medication;

          -  females of childbearing potential must agree to utilize an effective method of
             contraception throughout the study and for 90 days following discontinuation of study
             drug;

          -  patients at risk of developing CMV disease (all transplant recipients other than
             those who are D-R- for CMV).

        Exclusion Criteria:

          -  patients who have previously participated in this study;

          -  patients who are participating in another clinical trial (except with the approval of
             the Sponsor);

          -  severe, uncontrolled diarrhea (more than 5 watery stools per day);

          -  pregnant or lactating females.
      
